Trial Profile

NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma. A Multicenter Open-label Single Arm Phase Ib/IIa Trial

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 30 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
Indications Soft tissue sarcoma
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms NAPAGE

Most Recent Events

27 Sep 2022 Status changed from active, no longer recruiting to discontinued.
13 Sep 2022 Final results(n=39) of >2 year median follow assessing safety and activity of gemcitabine and nab-paclitaxel (nab-pc) in advanced, relapsed soft tissue sarcoma presented at the 47th European Society for Medical Oncology Congress
29 Oct 2021 Planned primary completion date changed from 1 Oct 2021 to 1 Oct 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com